CDK4/6 inhibitorFDA-approvedSecond-line
Palbociclib
How it works
Blocks the CDK4/6 enzymes that drive cell division in cancer cells, causing them to die.
Cancer types
Breast Cancer— Hormone receptor-positive
Efficacy
Palbociclib has been shown to improve progression-free survival in patients with hormone receptor-positive, HER2-negative metastatic breast cancer, particularly when combined with letrozole.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Antacid Use and Genetic Variants Affect Survival in Breast Cancer Patients | Breast Cancer | phase-3 | Concomitant antacid treatment reduced progression-free survival (26.2 vs. 32.6 months, p = 0.059) | Source → |
| Testing Anastrozole and Palbociclib in Advanced Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing Palbociclib and Bicalutamide for Metastatic Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Palbociclib Shows Promise in Treating Ovarian Cancer | Ovarian Cancer | phase-2 | The disease control rate was 38% (90% CI, 25 to 100) and the overall response rate was 11% (95% CI, 2 to 29). | Source → |
| Ribociclib and Palbociclib Show Similar Efficacy in Treating Metastatic Breast Cancer | Breast Cancer | observational | The 24-month PFS rates were comparable between the ribociclib and palbociclib cohorts (55.4% vs. 55.2%, respectively). | Source → |
| Palbociclib and Fulvestrant for Metastatic Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Evaluating CDK4/6 Inhibitors for Metastatic Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Study of Palbociclib and Locoregional Treatment for Advanced Breast Cancer | Breast Cancer | preclinical | — | Source → |
| Comorbidities Affect Outcomes for Breast Cancer Patients on Palbociclib | Breast Cancer | observational | Median overall survival durations were 48.8 months for patients with a Charlson Comorbidity Index score of 0, 39.0 months for patients with a score of 1-2, and 31.6 months for patients with a score of 3+. | Source → |
| Testing Palbociclib and Avelumab in Metastatic Triple Negative Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Using Text Messages to Help People Take Palbociclib for Breast Cancer | Breast Cancer | preclinical | — | Source → |
| Testing Palbociclib and Binimetinib in RAS-Mutant Cancers | Pancreatic Cancer | phase-2 | — | Source → |
| Palbociclib in Metastatic Prostate Cancer: A Clinical Trial | Prostate Cancer | phase-2 | — | Source → |
| New Long-Acting Palbociclib Injection for Metastatic Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Lab Test Models Breast Cancer Cells to Study Palbociclib Effectiveness | Breast Cancer | lab-study | — | Source → |
| New Insights into Treating Low-Grade Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Palbociclib and Neutropenia in Metastatic Breast Cancer | Breast Cancer | observational | The 30-month PFS rate was 75% with the dose of 100 mg, 90.9% with 75 mg, and 97.2% with the dose of 125 mg. | Source → |
| Palbociclib's Potential in Leukemia Treatment | Leukemia | review | — | Source → |
| Inavolisib Combination Not Cost-Effective for Advanced Breast Cancer | Breast Cancer | phase-3 | Inavolisib provided an additional 0.6 QALYs compared to placebo. | Source → |
| Palbociclib Effectiveness in Indian Breast Cancer Patients | Breast Cancer | observational | The real-world response rate and the real-world clinical benefit rate across treatment lines were 68% and 75.3%, respectively. | Source → |
| Cyclin Dependent Kinase Inhibitors in Metastatic Breast Cancer | Breast Cancer | observational | In patients receiving palbociclib, a better median progression-free survival (PFS) was observed in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 1 (27.3 months,p-value <0.0001), de novo disease (17.5 months,p-value 0.0155), first line hormonal therapy (22.5 months,p-value <0.0001) and no prior chemotherapy (20.3 months,p-value 0.0001). | Source → |
| Combining Wip1 and Palbociclib May Improve Breast Cancer Treatment | Breast Cancer | lab-study | The combined treatment produced a concentration-dependent reduction in cell viability and a marked increase in both early and late apoptotic populations compared with monotherapies. | Source → |
| Metformin Enhances Effect of Breast Cancer Treatment | Breast Cancer | lab-study | — | Source → |
| Intermittent Palbociclib Use in Metastatic Breast Cancer During Economic Crisis | Breast Cancer | observational | Intermittent discontinuation statistically reduces PFS by 26%. | Source → |
| Real-world effectiveness of palbociclib in breast cancer treatment | Breast Cancer | meta-analysis | First-line palbociclib+AI MMPFS (22.5 months, 95% CI = 19.5 to 31.8) aligned with PALOMA-1/2 pooled mPFS (23.9, 95% CI = 20.2 to 27.6). | Source → |
| Understanding Resistance to Breast Cancer Treatment | Breast Cancer | lab-study | — | Source → |
| Real-world study of palbociclib and fulvestrant for breast cancer | Breast Cancer | observational | Median real-world progression-free survival was 19.6 months (95% CI 15.2-23.6) | Source → |
| Palbociclib and Endocrine Therapy for Metastatic Breast Cancer in Japan | Breast Cancer | observational | The median progression-free survival was 26.6 months. | Source → |
| New Combination Therapy Shows Promise for Lung Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| G Protein Estrogen Receptor Linked to Resistance to Breast Cancer Treatment | Breast Cancer | lab-study | — | Source → |
| Palbociclib plus endocrine therapy effective in Japanese breast cancer patients | Breast Cancer | observational | Median progression-free survival was 24.5 months for first-line treatment and 14.5 months for second-line treatment. | Source → |
| Study Examines Combination Therapy for Advanced Breast Cancer | Breast Cancer | phase-2 | The median progression-free survival on F + P + A was 8.1 months (HR 0.75 [90% CI, 0.50 to 1.12]; = .23). | Source → |
| Palbociclib plus aromatase inhibitors may improve outcomes for African American breast cancer patients | Breast Cancer | observational | Median overall survival was not reached in the palbociclib + AI group versus 28.2 months in the AI group. | Source → |
| CDK4/6 Inhibitors May Work Later in Cell Cycle Than Thought | Breast Cancer | lab-study | — | Source → |
| Reusing a Cancer Drug May Help Some Breast Cancer Patients | Breast Cancer | phase-2 | The clinical benefit rate was 34.4% and 13.0% of tumors showed loss of Rb protein expression. | Source → |
| Rare Skin Reaction Linked to Breast Cancer Treatment | Breast Cancer | observational | — | Source → |
| Combining two drugs may slow triple-negative breast cancer | Breast Cancer | animal-study | — | Source → |
| Combining Two Cancer Drugs May Help Some Patients with Advanced Colorectal Cancer | Colorectal Cancer | phase-2 | The 4-month disease control rate was 20%. | Source → |
| Palbociclib Effectiveness in Real-World Breast Cancer Treatment | Breast Cancer | observational | — | Source → |
| Palbociclib treatment duration linked to dose reductions in breast cancer | Breast Cancer | observational | The time-to-treatment discontinuation was 8.9 months in the case of P + f (95% CI: 7.1-12.7) and 13.7 months in the case of P + ia. | Source → |
| Continuing CDK Inhibitors After Disease Progression in ER-positive Breast Cancer | Breast Cancer | observational | The overall response rate was 16.0% and the clinical benefit rate was 44.0%. | Source → |
| Combination Therapy May Help Overcome Resistance to Ovarian Cancer Treatment | Ovarian Cancer | lab-study | — | Source → |
| Combining Palbociclib and Vemurafenib in Metastatic Melanoma Treatment | Melanoma | phase-1/2 | The median progression-free survival was 2.8 months, and 5 (27.8%) patients showed a clinical response. | Source → |
| Palbociclib Doesn't Prevent Recurrence in High-Risk Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Comparing Two Cancer Treatments in Younger Women | Breast Cancer | observational | The median progression-free survival was 24.05 months for palbociclib and 24.41 months for ribociclib. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.